Stephenson Harwood houses an ‘excellent’ team, which handles a variety of issues for clients concerning trade marks, biologics, and data protection. ‘Excellent’ practice head Alexandra Pygall has broad expertise in advising clients on collaboration, licensing and partnering agreements, in addition to the IP elements of M&A. Dan Holland is particularly knowledgeable when it comes to manufacturing and supply agreements for vaccines, and has ‘extensive experience’ in international outsourcing agreements.
Testimonials
Collated independently by Legal 500 research team.
‘The team forms a good rapport immediately which allows internal and external teams to work seamlessly. SH listens, responds and challenges accordingly. Excellent support.'
‘Develops a good rapport immediately. Ability to have honest responses to challenges. Respectful and engaging.’
‘The team has particular expertise in developing and negotiating service contracts within the biologics life sciences industry.'
‘Dan Holland has extensive experience both with US and UK companies in the biologics contract manufacturing sector.'
‘The entire group is outstanding. They are always extremely quick, up to speed and ready to build a tailor-made team according to the case at hand. We appreciate their excellent understanding of the industry.’
‘Rob Jacob and Alexandra Pygall are both excellent.’
‘Alexandra Pygall is great and has a combination of litigation and contracting experience.'
'Naomi Leach - it's helpful to have her tech and data privacy experience.'
Key clients
- Acacia Pharma Group plc
- AM-Pharma
- Apposite Capital
- Bicycle Therapeutics
- Biomer
- BXT Accelyon
- Eisai Europe Ltd
- e-therapeutics plc
- Futura Medical Plc
- GSK
- Incyte Corporation
- Johnson & Johnson Innovation
- LifeArc
- Oxford Biomedica plc
- Shield Therapeutics Plc
- BioNTech
- GE HealthCare
Work highlights
- Advising Oxford Biomedica on its new three year Master Services & Development Agreement with AstraZeneca UK Ltd which would facilitate potential future manufacturing opportunities for the AstraZeneca Covid-19 vaccine.
- Acting for Primer Design Limited and its French parent company, Novacyt S.A. in a £134m claim brought by the Secretary of State for Health and Social Care and PD's £81m counterclaim to recover sums due from DHSC under unpaid invoices.
- Advised Bicycle Therapeutics on its recent strategic collaboration agreement with Novartis.
Lawyers
Practice head
The lawyer(s) leading their teams.
Alexandra Pygall